In the News

Read ICON expert Chuck Stevens' comments on how he and his team are supporting patient/consumer access in this recent PharmaTimes article.

MolecularMD is profiled as one of eight Companion Diagnostic (CDx) developers to watch for their track record, including recent activity in the field, in this July 2019 Clinical OMICs article.

Clinical Leader discusses how Clinical RM (now ICON GPHS) was selected to conduct a chlamydia study, AMPREVENCE, based on recognized experience in STD trials.

Read BioCentury's latest media article written by ICON's Lucy Clossick Thomson & Susan Campbell, discussing biotechs' use for patient engagement to improve cancer trial recruitment.

ICON has been recognised in Forbes' 2019 list of America’s Best Employers for Women.

Read ICON expert Sarah Ikard's take on the innovative role patient centricity may play in the evolution of future trials here.

ICON experts discuss the evolution of patient reported outcomes & the role of patient outcome research in informing payers, patients, clinicians & regulators.

ICON's Martin Lachs & Brandon Fletcher discuss ACT clinical trials in this July 2019 DDN News article.

Marisa Pearce at Molecular MD, an ICON company, argues that, although immunotherapy is nothing new, it has much untapped potential yet to be explored.

Learn how the use of technology has become ubiquitous in clinical trials as the industry looks to streamline and improve processes.